home   |   contact us   |   sitemap     

   about Formula Pharmaceuticals  technology  pipeline NewsCareers  




Board of Directors

Advisory Committee


Scientific Advisory Board


Business Development  





MAURITS W. GEERLINGS President and Chief Executive Officer

President and Chief Executive Officer

Dr. Geerlings co-founded Formula Pharmaceuticals in 2009 and has more than 18 years of biopharmaceutical experience including general management, business development, international operations, biotech start-up, financing, government affairs, academic research, and strategic planning. Previously, Dr. Geerlings was a co-founder and former Director and Chief Operating Officer of Actinium Pharmaceuticals, an oncology focused biotechnology company; lead business development at Infinity Pharmaceuticals, a publicly traded oncology focused company; and served as Vice President, Business Development at Prism Pharmaceuticals, a privately-held biopharmaceutical company focusing on acute care medicines. Prior to joining Prism Pharma, Dr. Geerlings led business development activities in a variety of therapeutic areas with a predominant focus on oncology at Cephalon Inc., Alexion Pharmaceuticals and the Ludwig Institute for Cancer Research. Dr. Geerlings earned his M.D. from The University of Utrecht, Faculty of Medicine, Utrecht, The Netherlands, and his M.B.A. from The George Washington University in Washington, DC. He holds an M.S. from the University of Utrecht, The Netherlands.


Dr. Collins has decades of experience in corporate financing and leadership within life science companies. Earlier in his career, Dr. Collins was the Founder and Chief Executive Officer of Data Science Ventures, Inc. (DSV I). He was a Founder of DSV Associates (DSV II); DSV Partners III (DSV III); DSV Partners IV (DSV IV) and has been the Managing Partner of each entity. These organizations provide venture capital and management assistance to early-stage high-technology companies. In 1997, Dr. Collins became a Special Limited Partner of Cardinal Partners, the successor to the DSV series of partnerships. In 2003, Dr. Collins became a General Partner of Battelle Ventures which he founded. Dr. Collins has served as a Director at Alkermes, Apollon Inc. and The Liposome Company, three successful life science companies. Dr. Collins earned his B.S. from the University of Delaware and his Masters and Doctorate Degrees from Princeton University.


Mr. Greenacre served as Chairman of BMP Sunstone Corporation, a pharmaceutical company recently acquired by Sanofi-Aventis. Mr. Greenacre also has served since 2002 as Chairman of Life Mist Technologies, Inc., a fire suppression equipment company. Previously, Mr. Greenacre served as Chief Executive Officer and Director of Delsys Pharmaceutical Corporation, a formulation and drug delivery system company, and as President, Chief Executive Officer and Director of Zynaxis Inc., a biopharmaceutical company. Mr. Greenacre was Chairman Europe, SmithKline Beecham Pharmaceutical Company. He joined SmithKline & French in 1973, where he held positions of increasing responsibility in its European organization. Mr. Greenacre has served on a number of start-up company Boards and currently serves on Acusphere, Inc. (a drug delivery company) and Curis, Inc. (a biotechnology company). He earned his M.B.A. and B.A. from Harvard University.


Dr. Mosconi co-founded Formula Pharmaceuticals and brings more than 22 years of experience in the biopharmaceutical industry. He was also co-founder, President and Chief Operating Officer at ACUREON, a search fund supported by three major U.S. VCs. Prior to this, he served as Senior Vice President, Business Development, at Vicuron Pharmaceuticals, Inc. (acquired by Pfizer in 2005), the result of a merger between Biosearch Italia and Versicor Inc. Previously, Dr. Mosconi served as Vice President, Medical Affairs and Business Development at Biosearch Italia and as European Executive Director for R&D Anti-infectives and Immunology at Bristol-Myers-Squibb. Dr. Mosconi began his career at Marion Merrell Dow (now Sanofi-aventis) serving as Italian Medical Leader, Anti-infectives, and then transitioning to European Therapeutic Leader. He earned his M.D. from the Medical School University of Milan and his Ph.D. in ENT, head and neck surgery from the University of Milan. He holds a B.A. in chemistry.